Inventor · disambiguated record
Jan Johan Adriaan Tuiten
Also filed as: TUITEN JAN J A · TUITEN JAN JOHAN ADRIAAN
13 granted patents·8 pending applications·11 citations·filing 2006–2023
88Inventor score
Files withTUITEN JAN JOHAN ADRIAAN6EB IP LYBRIDO B V5EMOTIONAL BRAIN BV4EB IP HYBRITABS B V2EB IP LYBRIDOS B V2
Top patents by PatentIndex Score
21 records- 0181US8227453B2Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionTUITEN JAN JOHAN ADRIAAN·Filed 2006·Granted Jul 24, 2012·4 cites·11 claims
- 0278US9700566B2Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionEB IP LYBRIDO B V·Filed 2015·Granted Jul 11, 2017·2 cites·9 claims
- 0377US9737548B2Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionEB IP LYBRIDO B V·Filed 2016·Granted Aug 22, 2017·2 cites·9 claims
- 0477US9597335B2Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunctionEMOTIONAL BRAIN BV·Filed 2015·Granted Mar 21, 2017·1 cites·8 claims
- 0572US8653051B2Use of 3-alpha-androstanediol in combination with a PDE5 inhibitor, in the treatment of sexual dysfunctionTUITEN JAN JOHAN ADRIAAN·Filed 2007·Granted Feb 18, 2014·0 cites·5 claims
- 0672US8648060B2Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunctionTUITEN JAN JOHAN ADRIAAN·Filed 2007·Granted Feb 11, 2014·0 cites·4 claims
- 0772US8575139B2Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunctionTUITEN JAN JOHAN ADRIAAN·Filed 2007·Granted Nov 5, 2013·0 cites·9 claims
- 0871US9192669B2Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionTUITEN JAN JOHAN ADRIAAN·Filed 2012·Granted Nov 24, 2015·1 cites·7 claims
- 0968US9211334B2Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunctionEMOTIONAL BRAIN BV·Filed 2013·Granted Dec 15, 2015·0 cites·11 claims
- 1067US2014121189A1Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunctionEMOTIONAL BRAIN BV·Filed 2014·Application pending·0 cites
- 1167US2014121190A1Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunctionEMOTIONAL BRAIN BV·Filed 2014·Application pending·0 cites
- 1266US9333203B2Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionTUITEN JAN J A·Filed 2006·Granted May 10, 2016·1 cites·7 claims
- 1366US8669242B2Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunctionTUITEN JAN JOHAN ADRIAAN·Filed 2012·Granted Mar 11, 2014·0 cites·10 claims
- 1464US2023330028A1Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systemsEB IP HYBRITABS B V·Filed 2023·Application pending·0 cites
- 1563US2019388435A1Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionEB IP LYBRIDO B V·Filed 2019·Application pending·0 cites
- 1663US2019262359A1Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunctionEB IP LYBRIDOS B V·Filed 2019·Application pending·0 cites
- 1762US10314848B2Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunctionEB IP LYBRIDOS B V·Filed 2017·Granted Jun 11, 2019·0 cites·11 claims
- 1861US10441592B2Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionEB IP LYBRIDO B V·Filed 2017·Granted Oct 15, 2019·0 cites·3 claims
- 1948US2017042911A1Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunctionEB IP LYBRIDO B V·Filed 2016·Application pending·0 cites
- 2047US2020306195A1Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systemsEB IP HYBRITABS B V·Filed 2017·Application pending·0 cites
- 2144US2016279146A1Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactionsLIMOXIFEN B V·Filed 2014·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →